Stock Analiz

Interpace Biosciences, Inc. IDXG

· data as of November 13, 2026

$6.05Market cap $25M
Open the interactive analysis →

Interpace Biosciences, Inc. (IDXG) is a company listed in the US with a market value of about $25M. In the twelve months to June 30, 2026 it had revenue of $36M and net income of $24M, a net margin of 67.6%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is financial health (5/5); the weakest is future growth (1/5).

Key numbers: a P/E of 1.0, a price to free cash flow of 6.0, 5-year revenue growth of 4% a year, a 5-year average ROIC of 118%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 5% below the current price.

About Interpace Biosciences

Interpace Biosciences is listed in the US. Revenue went from $24M in 2019 to $39M in 2025, growth of about 8.1% a year. It was profitable in 3 of the last 7 years in our data. Its share count rose by 553% over three years (dilution for shareholders). It spends 2% of revenue on research and development.

Score: 2.2 / 5

Value2/5
Future growth1/5
Track record2/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/FCF below 20
  • Profit margin improving
  • 5-year average ROIC above 12%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times

Checks not passed

  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)1.0
Forward P/E—
P/FCF6.0
P/S0.7
P/B1.1
EV/EBITDA5.0
PEG—
Dividend yield0.00%
FCF yield16.7%
Shareholder yield0.0%
Intrinsic value vs. price−5%

Growth and quality

Revenue growth (1 yr)-17.5%
Revenue growth (5 yrs, per year)3.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6.3%
ROIC (5-yr avg.)118.2%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$36M$39M$47M$40M$32M$33M$32M$24M
Net income$24M$25M$7M$2M-$22M-$15M-$26M-$27M
Free cash flow$4M$5M$4M$3M-$8M-$9M-$16M-$19M
EPS (diluted)$0.89$0.89$0.40$0.45$-5.18$-3.61$-7.32$-7.25
Net margin67.6%63.5%14.3%4.9%-69.0%-45.1%-81.6%-110.4%
ROIC—13.7%222.7%————-722.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Interpace Biosciences’s P/E ratio?

About 1.0, based on the last twelve months of diluted earnings per share.

Is Interpace Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 5% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Interpace Biosciences pay a dividend?

Not currently.

Is Interpace Biosciences a good stock to buy?

We do not give buy or sell advice. Interpace Biosciences scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.